pharma · Retinitis Pigmentosa · Dyslipidaemia
HRA Pharma
Laboratoire HRA Pharma
HRA Pharma clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- CHATILLON, USA
- Employees
- 121
- Programs
- 11
- Drugs
- 17
- Patents
- 0
HRA Pharma projects
5 ClinicalTrials.gov programs sponsored by HRA Pharma.
HRA Pharma has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Placebo of NAL, NACYSTELYN
Laboratoire HRA Pharma
Obstructive Sleep Apnea
1 trial -
Preservative-free, ophthalmic solution
Laboratoire HRA Pharma
Paediatric myopia
1 trial -
SB-421a-006
Laboratoire HRA Pharma
Retinitis Pigmentosa
1 trial -
SB-421a-006
Laboratoire HRA Pharma
Retinitis Pigmentosa
1 trial -
Verkazia 1 mg/mL eye drops, emulsion
Laboratoire HRA Pharma
Vernal Keratoconjunctivitis (VKC)
1 trial
Frequently asked questions
How many clinical projects does HRA Pharma have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.